OC
AUPH icon

Oppenheimer & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History

Oppenheimer & Co’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Sell
12,520
-900
-7% -$14.4K ﹤0.01% 1636
2026
Q1 		$199K Hold
13,420
– – ﹤0.01% 1578
2025
Q4 		$214K Hold
13,420
– – ﹤0.01% 1407
2025
Q3 		$148K Hold
13,420
– – ﹤0.01% 1586
2025
Q2 		$114K Buy
13,420
+10
+0.1% +$80 ﹤0.01% 1554
2025
Q1 		$108K Sell
13,410
-1,000
-7% -$8.1K ﹤0.01% 1513
2024
Q4 		$129K Sell
14,410
-300
-2% -$2.45K ﹤0.01% 1496
2024
Q3 		$108K Hold
14,710
– – ﹤0.01% 1450
2024
Q2 		$84K Sell
14,710
-500
-3% -$2.63K ﹤0.01% 1389
2024
Q1 		$76.2K Sell
15,210
-3,700
-20% -$25.1K ﹤0.01% 1399
2023
Q4 		$170K Buy
18,910
+10
+0.1% +$82 ﹤0.01% 1302
2023
Q3 		$147K Hold
18,900
– – ﹤0.01% 1296
2023
Q2 		$183K Sell
18,900
-2,500
-12% -$25.9K ﹤0.01% 1299
2023
Q1 		$235K Buy
21,400
+3,000
+16% +$26.4K 0.01% 1205
2022
Q4 		$79.5K Sell
18,400
-3,200
-15% -$18.6K ﹤0.01% 1300
2022
Q3 		$162K Sell
21,600
-2,000
-8% -$17.3K ﹤0.01% 1251
2022
Q2 		$237K Buy
23,600
+1,000
+4% +$11.2K 0.01% 1193
2022
Q1 		$280K Buy
22,600
+2,600
+13% +$40.2K 0.01% 1227
2021
Q4 		$457K Buy
20,000
+2,200
+12% +$52.1K 0.01% 1076
2021
Q3 		$394K Sell
17,800
-12,764
-42% -$203K 0.01% 1112
2021
Q2 		$396K Buy
30,564
+274
+0.9% +$3.49K 0.01% 1124
2021
Q1 		$393K Buy
+30,290
New +$439K 0.01% 1068

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co's AUPH Position: Q2 2026 in Review

Oppenheimer & Co reduced its Aurinia Pharmaceuticals (AUPH) stake by 6.7% in Q2 2026, selling an estimated $14.4K and leaving 12,520 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Oppenheimer & Co first reported a position in AUPH in Q1 2021 and has held it in 22 quarters since. The position peaked at $457K in Q4 2021. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Oppenheimer & Co held 12,520 shares of Aurinia Pharmaceuticals worth $212K as of Q2 2026.
  • Oppenheimer & Co sold 900 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $14.4K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1636 holding.
  • Oppenheimer & Co first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Oppenheimer & Co's Aurinia Pharmaceuticals position peaked at $457K in Q4 2021.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.